Orlistat plus progestin for fertility-sparing treatment of early endometrial cancer or atypical hyperplasia
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of uterine cancer (grade 1 or 2 endometrioid) or a precancer called atypical hyperplasia, confirmed by two pathologists.
- The disease is only in the inner lining of the uterus, not deeply in the muscle, and has not spread beyond the uterus.
- You are 45 years old or younger.
- You have already taken a standard hormone treatment (medroxyprogesterone or megestrol) for at least 3 months, but it did not completely clear the disease.
- Your cancer cells have low levels of progesterone receptors (a protein that hormone therapy targets).
- You have a body mass index (BMI) of 24 or higher, and you do not have severe liver, kidney, or bleeding problems.
- You want to preserve your fertility and are willing to follow the study rules, including using reliable contraception if you are not trying to get pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.
This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.